Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

efatutazone × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Head & Neck 2 Gastrointestinal 2 Endocrine 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Dexamethasone 773 Bortezomib 425 Lenalidomide 414 Cyclophosphamide 332 Melphalan 256 Calcium Dobesilate 229 daratumumab 211 pomalidomide 183 carfilzomib 160 fludarabine 123 fludarabine phosphate 118 Thalidomide 110 Peripheral Blood Stem Cell Transplantation 109 Filgrastim 104 ixazomib 85 Whole-Body Irradiation 81 Mycophenolic Acid 78 dexamethasone acetate 77 Granulocyte Colony-Stimulating Factor 77 Busulfan 77 Tacrolimus 67 dexamethasone 21-phosphate 63 Prednisone 61 Cyclosporine 59 auricularum 58 belantamab mafodotin 56 isatuximab 55 elotuzumab 54 Antilymphocyte Serum 50 Radiotherapy 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01504490 2017-02-14

Phase I Study of CS-7017 and Bexarotene

Georgetown University

Phase 1 Terminated

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡